Science That Evolves With the Evidence
The multiomic and agentic AI architecture behind the world’s first living cancer diagnostic.
Matched tumour–normal WES, whole-transcriptome RNA, and longitudinal agentic AI reanalysis, forming a continuously updating interpretation engine built for clinical precision.
The Next Frontier in Clinical Genomics
Cancer is not a static disease.
It evolves biologically, and the science behind it can evolve just as fast.
GenTraceDx brings together three pillars of modern molecular oncology:
Comprehensive DNA Profiling
Matched tumour–normal whole exome sequencing
Functional RNA Biology
Whole transcriptome RNA sequencing
Agentic AI Discovery Engine
Longitudinal reanalysis and interpretation
This integrated approach provides a high-resolution view of the tumor’s molecular landscape.
Tumour–Normal Whole Exome Sequencing (WES)
A Pan-Cancer, Unbiased View of the Coding Genome
Most commercial tests rely on restricted gene panels, missing rare variants and structural drivers outside their fixed coverage. GenTraceDx uses full exome sequencing of matched tumour and normal DNA to provide complete genomic visibility.
Comprehensive Genomic Depth
- Precise Somatic Calling: Accurate identification of tumour-specific mutations.
- Novel Variant Detection: Unbiased discovery of rare and "out-of-panel" drivers.
- Mutation Burden Analysis: Complete TMB profiling across the entire coding genome.
- Structural Variant Detection: High-resolution mapping of fusions and CNVs.
High-Fidelity Clinical Data
- Matched-Normal Resolution: Eliminates 30%–50% false-positive germline noise.
- Germline Filtering: Definitive distinction between inherited and somatic variants.
- Discovery Foundation: The high-fidelity dataset required for Agentic AI.
- Actionable Hotspots: Identifies therapeutic targets that are invisible to panel-based testing.
Whole Transcriptome RNA Sequencing (RNA-Seq)
RNA Reveals What DNA Alone Cannot
RNA provides the functional readout of tumour biology, revealing what is active and actionable.
Why RNA matters in the clinic:
DNA answers
"What is altered?" (The Genomic Blueprint)
RNA answers
"What is active?" (The Functional State)
The Result: Together, they provide a far more complete picture of tumour vulnerability.
Key capabilities enabled by RNA-Seq:
Pathway Activation Signatures
Identifies actionable therapeutic targets even when DNA mutations are inconclusive.
Gene Expression Outliers
Detects overexpressed targets to guide off-label DIN therapy decisions and SAP pathways.
Advanced Fusion Detection
Captures actionable fusions (ALK, ROS1, NTRK, RET) that are often structurally invisible to DNA panels.
Splice Variant Insights
Identifies isoforms and variants relevant to drug resistance and therapeutic sensitivity.
Immune Microenvironment
Profiles infiltration signatures to inform immunotherapy selection and personalized vaccine design.
Longitudinal AI Evidence and Reanalysis Engine
The World’s First Autonomous Knowledge & Discovery Engine for Cancer
Legacy genomic reports are static snapshots. GenTraceDx is a continuously updating, patient-specific clinical intelligence system.
GenTraceDx unifies a real-time global knowledge base with a proactive discovery engine:
- Autonomous Knowledge Synchronization: Our agentic AI continuously monitors the global evidence frontier, including FDA/EMA approvals, NCCN guidelines, and biomarker literature to ensure the knowledge base is never outdated.
- The Living Diagnostic: Unlike static reports, GenTraceDx provides continuous longitudinal surveillance, automatically reanalyzing each patient’s WES + RNA as new evidence emerges and alerting the care team to new opportunities.
- Agentic Discovery Engine: By analyzing each patient’s clinical history and multiomic profile against global medical knowledge, the system identifies novel therapeutic pathways and off-label opportunities invisible to legacy systems.
How the Discovery Engine Acts:
- Synchronize: Continuously updates the global oncology knowledge base.
- Perceive: Identifies new evidence relevant to the patient’s multiomic profile in real time.
- Discover: Performs cross-disciplinary analysis to uncover new clinical pathways and therapeutic targets.
- Act: Proactive Agentic Alerts notify the care team the moment a new clinical trial match or therapeutic opportunity is identified.
GenTraceDx is a continuously updating clinical intelligence system for cancer.
Variant Interpretation Framework
Built on Global Standards, Expanded for Multiomics
We build on global clinical standards and extend them through real-time multiomic interpretation and discovery:
DNA Variant Interpretation
- Global Standards: Clinical significance based on ACMG/AMP and established oncology evidence levels.
- Integrated Annotations: Variant and evidence-path data synchronized from leading global repositories.
- Scientific Literature: Real-time, full-text functional evidence curated from the global body of clinical research.
RNA Functional Interpretation
- Fusion Detection: Identification via validated, high-fidelity clinical pipelines.
- Expression Profiling: Continuous aberration and outlier analysis to identify functional drivers.
- Pathway Mapping: Functional activation scoring to reveal active therapeutic targets.
- Immune Microenvironment: Advanced signature profiling for immunotherapy and vaccine insights.
Therapeutic Discovery Logic
- Global Therapy Matching: On-label and off-label options across the full clinical evidence base.
- Special Access (SAP): Pathways for non-marketed medications and expanded clinical access.
- Real-Time Trial Discovery: Proactive identification of emerging global clinical trials.
- Novel Treatment Pathways: Unearthing therapeutic insights based on the patient’s full molecular landscape.
- Vaccine Architecture: Predictive signals for personalized neoantigen immunotherapy.
Explore Our Services
For scientific or collaboration inquiries, contact science@gentrace.com.
Scientific Differentiators
- Matched tumor/normal WES, true somatic mutation calling
- Proprietary peptide design for synthetic long neoantigen vaccines
- RNA-guided therapy filtering for enhanced biological relevance
- Personalized outputs for each individual patient
- Designed for clinical use, with physician-first delivery model
Reanalysis Triggers
Autonomous Clinical Vigilance: When Does the Engine Act?
The GenTraceDx Discovery Engine provides continuous surveillance of global science, triggering an automated re-interrogation of the patient profile whenever new evidence emerges.
A reanalysis is triggered whenever the system detects:
• New Global Drug Approvals:
FDA/EMA approvals, especially in tumour-agnostic contexts.
• Updated Clinical Guidelines:
Shifts in NCCN/ESMO standards, including biomarker expansion.
• Newly Published Evidence:
Literature linking specific mutations to therapeutic resistance or sensitivity.
• Active Clinical Trials:
Newly opened global trials matching the patient’s molecular and clinical profile.
• Emerging Real-World Evidence (RWE):
Case reports or cohort studies demonstrating response in rare or complex tumour types.
• Functional RNA Discoveries:
New insights into fusion partners, pathway roles, and isoform-level sensitivity.
The system utilizes priority scoring to automatically categorize new evidence:
- Tier 1: Clinically Actionable (Immediate therapeutic or trial opportunity)
- Tier 2: Potentially Actionable (Emerging consensus or SAP opportunity)
- Tier 3: Exploratory (Early-phase signals or research pathways)
- Tier 4: Observational (Not currently relevant to treatment architecture)
If evidence is actionable or potentially actionable → the care team receives an alert.
Clinical Reporting & Notifications
Clear. Evidence-Based. Clinically Prioritized.
Every update includes:
- Summary of new evidence
- Why the evidence matters for this specific tumour
- Potential therapy implications
- DIN status (on-label / off-label)
- SAP status if applicable
- Mechanistic rationale
- Trial-matching updates
- Tiered confidence scoring
- Evidence references
Reports integrate directly with clinician portals for seamless workflow.
Data Quality, Security & Compliance
Built to Meet the Highest Clinical Standards
Through the combined expertise of the Genome Sciences Centre (GSC) and Genetrack, the GenTraceDx platform, testing infrastructure, and clinical workflows are being developed and validated to meet the highest regulatory and clinical standards, including:
- CAP
- CLIA
- DAP (BC)
- MDEL compliance
- FDA Class I exempt kit requirements
- PIPEDA + PHIPA privacy frameworks
- HIPAA-equivalent protections
Multiomic Advantage Summary
Why Multiomics + Longitudinal Agentic AI is Clinically Superior
| Legacy Static Panels | GenTraceDx Platform |
|---|---|
| Limited gene lists | Whole Exome (all coding genes) |
| No RNA insight | Full transcriptome |
| One-time snapshot | Continuous, evidence-driven reanalysis |
| No matched normal | Matched tumour–normal |
| Narrow therapeutic view | Comprehensive therapeutic landscape |
| Limited trial matching | Multiomic trial-matching engine |
| No update alerts | AI-driven clinician notifications |
| 88% “no actionable findings” | Expanded therapeutic insights |
Multiomics captures more signals. Continuous, evidence-driven reanalysis delivers updated, actionable insights.
Together, they create a living diagnostic.
FOR INSTITUTIONAL PARTNERS
The Infrastructure of Therapeutic Discovery
GenTraceDx is designed to provide the high-fidelity multiomic and AI infrastructure powering the next generation of precision oncology
- Institutional Research Partnerships: Enabling large-scale clinical trials with matched WES + RNA.
- Biotechnology Data Ecosystems: Providing de-identified multiomic data to support therapeutic and biomarker development.
- Agentic AI Model Access: Enabling collaborative AI model development based on real-world clinical and molecular data.
- Pharma Discovery Pipelines: Accelerating neoantigen, biomarker, and therapeutic discovery for targeted therapies.
- Global Multiomic Standards: Defining the future standard for longitudinal clinical interpretation.